Table 4.
Multiple linear mixed-effect regression analysis of the relationship between SSRIs and PSF in the PSD subgroup during the 24-month follow-up period.
| β (95% CI) | SE | t value | P value | |
|---|---|---|---|---|
| Model 1 | ||||
| Baseline FSS | 0.165 (−0.188–0.519) | 0.180 | 0.92 | 0.359 |
| Treatment | −0.016 (−0.030–0.002) | 0.007 | −2.313 | 0.021 |
| Time effect | −0.035 (−0.047–0.024) | 0.006 | −5.94 | <0.001 |
| Model 2 | ||||
| Baseline FSS | 0.001 (−0.383–0.386) | 0.196 | 0.008 | 0.994 |
| Treatment | −0.018 (−0.035–0.001) | 0.009 | −2.05 | 0.041 |
| Time effect | −0.034 (−0.0495–0.020) | 0.007 | −4.69 | <0.001 |
Model 1: Unadjusted; Model 2: The model was adjusted for age, sex, body mass index, hypertension, diabetes mellitus, hyperlipemia, smoking, drinking, TOAST classification., NIHSS, HAMA and Lubben score.
CI, confidence interval; CHD, coronary heart disease; HAMA, Hamilton Anxiety Scale; NIHSS, NIH Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke Treatment; PSD, poststroke depression; PSF, poststroke fatigue; SE, standard error.